Analysis of Human Immunodeficiency Virus Type 1 Transcriptional Elongation in Resting CD4+ T Cells In Vivo

ABSTRACT A stable latent reservoir for human immunodeficiency virus type 1 (HIV-1) in resting memory CD4+ T cells presents a barrier to eradication of the infection even in patients on highly active antiretroviral therapy. Potential mechanisms for latency include inaccessibility of the integrated viral genome, absence of key host transcription factors, premature termination of HIV-1 RNAs, and abnormal splicing patterns. To differentiate among these mechanisms, we isolated extremely pure populations of resting CD4+ T cells from patients on highly active antiretroviral therapy. These cells did not produce virus but retained the capacity to do so if appropriately stimulated. Products of HIV-1 transcription were examined in purified resting CD4+ T cells. Although short, prematurely terminated HIV-1 transcripts have been suggested as a marker for latently infected cells, the production of short transcripts had not been previously demonstrated in purified populations of resting CD4+ T cells. By separating RNA into polyadenylated and nonpolyadenylated fractions, we showed that resting CD4+ T cells from patients on highly active antiretroviral therapy produce abortive transcripts that lack a poly(A) tail and that terminate prior to nucleotide 181. Short transcripts dominated the pool of total HIV-1 transcripts in resting CD4+ T cells. Processive, polyadenylated HIV-1 mRNAs were also present at a low level. Both unspliced and multiply spliced forms were found. Taken together, these results show that the nonproductive nature of the infection in resting CD4+ T cells from patients on highly active antiretroviral therapy is not due to absolute blocks at the level of either transcriptional initiation or elongation but rather relative inefficiencies at multiple steps.

[1]  Robert F. Siliciano,et al.  Characterization of Chemokine Receptor Utilization of Viruses in the Latent Reservoir for Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.

[2]  Junmin Peng,et al.  Tat Modifies the Activity of CDK9 To Phosphorylate Serine 5 of the RNA Polymerase II Carboxyl-Terminal Domain during Human Immunodeficiency Virus Type 1 Transcription , 2000, Molecular and Cellular Biology.

[3]  D. Nickle,et al.  Evidence for Human Immunodeficiency Virus Type 1 Replication In Vivo in CD14+ Monocytes and Its Potential Role as a Source of Virus in Patients on Highly Active Antiretroviral Therapy , 2002, Journal of Virology.

[4]  D. Richman,et al.  Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. , 1999, Science.

[5]  M. Clementi,et al.  Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo , 1996, Journal of virology.

[6]  J. Karn,et al.  Activation of Human Immunodeficiency Virus Transcription in T Cells Revisited: NF-κB p65 Stimulates Transcriptional Elongation , 2001, Journal of Virology.

[7]  R. Siliciano,et al.  Resting CD4+ T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes , 2004, Journal of Virology.

[8]  G. Pavlakis,et al.  Analysis of human immunodeficiency virus type 1 mRNA splicing patterns during disease progression in peripheral blood mononuclear cells from infected individuals. , 1996, AIDS research and human retroviruses.

[9]  M. Boyd,et al.  Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. , 2001, Blood.

[10]  D. Baltimore,et al.  The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth , 1997, Journal of virology.

[11]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[12]  D. Hamer,et al.  Molecular characterization, reactivation, and depletion of latent HIV. , 2003, Immunity.

[13]  K. Jeang,et al.  Activation of Integrated Provirus Requires Histone Acetyltransferase , 1998, The Journal of Biological Chemistry.

[14]  Y. Korin,et al.  Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus Latency , 2002, Journal of Virology.

[15]  G. Nabel,et al.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells , 1987, Nature.

[16]  E. Verdin,et al.  HIV reproducibly establishes a latent infection after acute infection of T cells in vitro , 2003, The EMBO journal.

[17]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[18]  A. Rice,et al.  Tat-Associated Kinase, TAK, Activity Is Regulated by Distinct Mechanisms in Peripheral Blood Lymphocytes and Promonocytic Cell Lines , 1998, Journal of Virology.

[19]  A. Jordan,et al.  The site of HIV‐1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation , 2001, The EMBO journal.

[20]  A. Rice,et al.  Viral transactivators specifically target distinct cellular protein kinases that phosphorylate the RNA polymerase II C-terminal domain. , 1996, Nucleic acids research.

[21]  D. Baltimore,et al.  Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency , 1990, Cell.

[22]  D. Margolis,et al.  The regulation of HIV-1 gene expression: the emerging role of chromatin. , 2002, DNA and cell biology.

[23]  R. Desrosiers,et al.  Efficient transcription and replication of simian immunodeficiency virus in the absence of NF-kappaB and Sp1 binding elements , 1996, Journal of virology.

[24]  M. Giacca,et al.  HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B. Peterlin,et al.  NF-κB Binds P-TEFb to Stimulate Transcriptional Elongation by RNA Polymerase II , 2001 .

[26]  N. Hernandez,et al.  RNA-targeted activators, but not DNA-targeted activators, repress the synthesis of short transcripts at the human immunodeficiency virus type 1 long terminal repeat , 1997, Journal of virology.

[27]  B. Peterlin,et al.  Control of RNA initiation and elongation at the HIV-1 promoter. , 1994, Annual review of biochemistry.

[28]  T. Rana,et al.  Tat-associated Kinase (P-TEFb): a Component of Transcription Preinitiation and Elongation Complexes* , 1999, The Journal of Biological Chemistry.

[29]  A. Burny,et al.  HIV‐1 Tat transcriptional activity is regulated by acetylation , 1999, The EMBO journal.

[30]  A. Fauci,et al.  Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Mario Roederer,et al.  T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis , 2004, Journal of Virology.

[32]  B. Peterlin,et al.  NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. , 2001, Molecular cell.

[33]  Anthony S. Fauci,et al.  Induction of HIV-1 Replication in Latently Infected CD4+ T Cells Using a Combination of Cytokines , 1998, The Journal of experimental medicine.

[34]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[35]  B. Peterlin,et al.  Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation. , 1999, Virology.

[36]  M. Groudine,et al.  Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Ho,et al.  Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy , 1999, Journal of Virology.

[38]  D. Richman,et al.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  E. Fenyö,et al.  Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1 , 1990, Journal of virology.

[40]  O. Bagasra,et al.  Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[41]  B. Peterlin,et al.  P-TEFb Containing Cyclin K and Cdk9 Can Activate Transcription via RNA* , 2002, The Journal of Biological Chemistry.

[42]  R. Gaynor,et al.  Absolute dependence on kappa B responsive elements for initiation and Tat‐mediated amplification of HIV transcription in blood CD4 T lymphocytes. , 1995, The EMBO journal.

[43]  B. Franza,et al.  The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV , 1988, Cell.

[44]  Giuseppe Nunnari,et al.  Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. , 2002, The Journal of infectious diseases.

[45]  R. Siliciano,et al.  Analysis of Human Immunodeficiency Virus Type 1 Gene Expression in Latently Infected Resting CD4+ T Lymphocytes In Vivo , 2003, Journal of Virology.

[46]  P. Luciw,et al.  Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Littman,et al.  Cytokine Signals Are Sufficient for HIV-1 Infection of Resting Human T Lymphocytes , 1999, The Journal of experimental medicine.

[48]  N. Hernandez,et al.  Mutations in the carboxy-terminal domain of TBP affect the synthesis of human immunodeficiency virus type 1 full-length and short transcripts similarly , 1996, Journal of virology.

[49]  Y. Korin,et al.  Interleukin-7 Induces Expression of Latent Human Immunodeficiency Virus Type 1 with Minimal Effects on T-Cell Phenotype , 2002, Journal of Virology.

[50]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[51]  F. Kashanchi,et al.  Chromatin remodeling and modification during HIV-1 Tat-activated transcription. , 2003, Current HIV research.

[52]  J. Romeo,et al.  Limitation of Tat-associated transcriptional processivity in HIV-infected PBMC. , 1999, Virology.

[53]  M Roederer,et al.  HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. , 2001, Immunity.

[54]  R. Redfield,et al.  Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns , 1991, Journal of virology.

[55]  Robert F. Siliciano,et al.  In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency , 1995, Nature Medicine.

[56]  A. Giordano,et al.  Transcriptional regulation by targeted recruitment of cyclin-dependent CDK9 kinase in vivo , 1999, Oncogene.

[57]  M. Giacca,et al.  Regulation of HIV‐1 gene expression by histone acetylation and factor recruitment at the LTR promoter , 2003, The EMBO journal.

[58]  D. Margolis,et al.  Counterregulation of Chromatin Deacetylation and Histone Deacetylase Occupancy at the Integrated Promoter of Human Immunodeficiency Virus Type 1 (HIV-1) by the HIV-1 Repressor YY1 and HIV-1 Activator Tat , 2002, Molecular and Cellular Biology.

[59]  O. Bagasra,et al.  HIV-1 latency due to the site of proviral integration. , 1993, Virology.

[60]  M. Stevenson,et al.  HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection , 2003, Nature.

[61]  Martin A. Nowak,et al.  Constant Mean Viral Copy Number per Infected Cell in Tissues Regardless of High, Low, or Undetectable Plasma HIV RNA , 1999, The Journal of experimental medicine.

[62]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[63]  D. Hamer,et al.  Rational Design of Drugs That Induce Human Immunodeficiency Virus Replication , 2003, Journal of Virology.

[64]  D. Trono,et al.  Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency , 1992, Journal of virology.

[65]  M. Mathews,et al.  Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. , 1997, Genes & development.

[66]  C. A. Macken,et al.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.

[67]  N. Hernandez,et al.  Characterization of the inducer of short transcripts, a human immunodeficiency virus type 1 transcriptional element that activates the synthesis of short RNAs , 1993, Molecular and cellular biology.

[68]  A. Rice,et al.  Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor , 1995, Journal of virology.

[69]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[70]  C. Crumpacker,et al.  Human immunodeficiency virus type 1 RNA in peripheral blood mononuclear cells of patients receiving prolonged highly active antiretroviral therapy. , 2001, The Journal of infectious diseases.

[71]  Yang Shi,et al.  The Human Factors YY1 and LSF Repress the Human Immunodeficiency Virus Type 1 Long Terminal Repeat via Recruitment of Histone Deacetylase 1 , 2000, Journal of Virology.

[72]  H. Liou,et al.  Regulation of the Immune System by NF-κB and IκB , 2002 .

[73]  M. Malim,et al.  HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: Implications for HIV-1 latency , 1991, Cell.

[74]  B. Peterlin,et al.  Transcriptional Profiles of Latent Human Immunodeficiency Virus in Infected Individuals: Effects of Tat on the Host and Reservoir , 2003, Journal of Virology.

[75]  R. Lempicki,et al.  Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[76]  D. Purcell,et al.  Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity , 1993, Journal of virology.

[77]  P. Luciw,et al.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product , 1987, Nature.

[78]  D. Baltimore,et al.  The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[79]  B. Peterlin,et al.  Dynamics of Human Immunodeficiency Virus Transcription: P-TEFb Phosphorylates RD and Dissociates Negative Effectors from the Transactivation Response Element , 2004, Molecular and Cellular Biology.

[80]  D. Richman,et al.  Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. , 2001, The Journal of infectious diseases.

[81]  E. Verdin,et al.  Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity , 1999, Current Biology.

[82]  J. Zack,et al.  Identification of T cell-signaling pathways that stimulate latent HIV in primary cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[83]  C. Caron,et al.  Tat-controlled Protein Acetylation* , 2002, The Journal of Biological Chemistry.

[84]  T. Rana,et al.  HIV-1 Tat Protein Interacts with Mammalian Capping Enzyme and Stimulates Capping of TAR RNA* , 2001, The Journal of Biological Chemistry.

[85]  F. Kashanchi,et al.  The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[86]  T. Rana,et al.  Tat stimulates cotranscriptional capping of HIV mRNA. , 2002, Molecular cell.

[87]  H. Liou,et al.  Regulation of the immune system by NF-kappaB and IkappaB. , 2002, Journal of biochemistry and molecular biology.